The FDA recently approved a new ORAL therapy, Brinsupri (brensocatib) from Insmed Inc., indicated for the treatment of non-cystic fibrosis bronchiectasis in adult and pediatric patients 12 years of age and older. Brinsupri is a dipeptidyl peptidase 1 (DPP1) inhibitor and is the first and only treatment for the condition. Non-Cystic Fibrosis Bronchiectasis is a serious, chronic lung disease that can lead to permanent lung damage.
Approximately 500,000 U.S. patients are diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB). This approval offers patients effective treatment to defer the frequent exacerbations when symptoms worsen. Symptoms include coughing, increased mucus, shortness of breath and fatigue. Until now, treatment options were limited to antibiotics, airway clearance devices, and in severe cases, surgery.
Insmed will price Brinsupri at $88,000 per year before discounts during a company conference call.
The company also confirmed that Brinsupri will launch via specialty pharmacy limited distribution. Three SPs have confirmed their selection by Insmed as a distributor of the therapy, PantherRx Rare, Maxor Specialty Pharmacy, and Amber Specialty Pharmacy.
CLICK HERE to access prescribing information
—————————————————————————————-
